Abbreviated New Drug Application(ANDA)
An application for FDA approval of a generic drug product that references an already-approved drug.
Usage Examples
- The generic manufacturer submitted an ANDA with a Paragraph IV certification.
- FDA approved the ANDA after reviewing the bioequivalence study.
- The ANDA referenced the Orange Book-listed strength of the RLD.
What is ANDA?
An Abbreviated New Drug Application (ANDA) is the pathway for generic drug approval under Section 505(j) of the FD&C Act. ANDAs allow generic manufacturers to gain approval without conducting full clinical trials by demonstrating bioequivalence to a Reference Listed Drug (RLD).
The ANDA must show that the generic product contains the same active ingredient(s), dosage form, strength, route of administration, and conditions of use as the RLD. Bioequivalence studies demonstrate that the generic achieves the same blood concentration levels as the brand-name drug.
ANDAs also include information about manufacturing, controls, labeling, and any applicable patent certifications (Paragraph I, II, III, or IV).
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 314 94, 21 CFR 320.
When This Matters
- The generic manufacturer submitted an ANDA with a Paragraph IV certification.
- FDA approved the ANDA after reviewing the bioequivalence study.
- The ANDA referenced the Orange Book-listed strength of the RLD.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
ANDAs require bioequivalence studies (typically pharmacokinetic studies showing similar absorption) rather than full clinical efficacy trials. Chemistry, manufacturing, and controls (CMC) data are also required.
A Paragraph IV certification states that patents listed for the RLD are invalid or will not be infringed by the generic product, potentially triggering patent litigation and 180-day exclusivity for the first filer.
Under GDUFA, FDA targets 10-month review for standard ANDAs and 8-month review for priority ANDAs.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
